Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Donanemab

The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes
1:20
The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes
Jack Tsao • 7 May 2025
The clinical experience with lecanemab therapy in patients with MCI and early-stage AD
3:19
The clinical experience with lecanemab therapy in patients with MCI and early-stage AD
Jack Tsao • 7 May 2025
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease
3:02
Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease
Johanne Kaplan • 7 May 2025
Advances in managing ARIA in patients with Alzheimer’s disease treated with donanemab
1:08
Advances in managing ARIA in patients with Alzheimer’s disease treated with donanemab
Suzanne Schindler • 13 Jan 2025
Recommendations for the appropriate use of donanemab in Alzheimer’s disease
1:30
Recommendations for the appropriate use of donanemab in Alzheimer’s disease
Suzanne Schindler • 13 Jan 2025
Current pharmacological approaches in Alzheimer's disease
6:42
Current pharmacological approaches in Alzheimer's disease
Paulo Caramelli • 8 Jan 2024
Time saved in Alzheimer’s disease in Phase III trial of donanemab
0:49
Time saved in Alzheimer’s disease in Phase III trial of donanemab
Suzanne Hendrix • 22 Oct 2023
Time saved with Alzheimer’s disease therapeutics
4:29
Time saved with Alzheimer’s disease therapeutics
Suzanne Hendrix • 22 Oct 2023
Blood-based biomarkers for treatment monitoring in Alzheimer’s disease
0:56
Blood-based biomarkers for treatment monitoring in Alzheimer’s disease
Suzanne Schindler • 27 Sep 2023
Topline donanemab results: most positive Phase III data to date
1:26
Topline donanemab results: most positive Phase III data to date
Rebecca Edelmayer • 27 Jun 2023
Potential clinical meaningfulness of donanemab data
1:11
Potential clinical meaningfulness of donanemab data
Rebecca Edelmayer • 27 Jun 2023
Prospects for Alzheimer’s disease monitoring and treatment in 2023
2:36
Prospects for Alzheimer’s disease monitoring and treatment in 2023
Stephen Salloway • 19 Jun 2023
Use of AD blood-based biomarkers for trial enrolment
4:01
Use of AD blood-based biomarkers for trial enrolment
Philip Tipton • 19 May 2023
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
3:49
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
Philip Tipton • 19 May 2023
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
2:48
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
Stephen Salloway • 10 May 2023
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway • 10 May 2023
The content of VJDementia is intended for healthcare professionals